REFERENCES
1. van Zelm MC, McKenzie CI, Varese N, Rolland JM, O’Hehir RE. Recent
developments and highlights in immune monitoring of allergen
immunotherapy. Allergy. 2019;74(12):2342-2354.
2. Valenta R, Karaulov A, Niederberger V, et al. Allergen Extracts for
In Vivo Diagnosis and Treatment of Allergy: Is There a Future? The
Journal of Allergy and Clinical Immunology: In Practice.2018;6(6):1845-1855.e1842.
3. Carnés J, Iraola V, Cho SH, Esch RE. Mite allergen extracts and
clinical practice. Annals of Allergy, Asthma & Immunology.2017;118(3):249-256.
4. Codina R, Lockey RF. Pollen used to produce allergen extracts.Annals of Allergy, Asthma & Immunology. 2017;118(2):148-153.
5. Frick M, Fischer J, Helbling A, et al. Predominant Api m 10
sensitization as risk factor for treatment failure in honey bee venom
immunotherapy. Journal of Allergy and Clinical Immunology.2016;138(6):1663-1671.e1669.
6. Rolland JM, Varese NP, Abramovitch JB, et al. Effect of Heat
Processing on IgE Reactivity and Cross-Reactivity of Tropomyosin and
Other Allergens of Asia-Pacific Mollusc Species: Identification of Novel
Sydney Rock Oyster Tropomyosin Sac g 1. Molecular Nutrition &
Food Research. 2018;62(14):1800148.
7. Vieths S, Hoffmann A, Holzhauser T, Muller U, Reindl J, Haustein D.
Factors influencing the quality of food extracts for in vitro and in
vivo diagnosis. Allergy. 1998;53(46 Suppl):65-71.
8. Uyttebroek AP, Sabato V, Faber MA, et al. Basophil activation tests:
time for a reconsideration. Expert Review of Clinical Immunology.2014;10(10):1325-1335.
9. MacGlashan DW. Basophil activation testing. Journal of Allergy
and Clinical Immunology. 2013;132(4):777-787.
10. Hoffmann HJ, Santos AF, Mayorga C, et al. The clinical utility of
basophil activation testing in diagnosis and monitoring of allergic
disease. Allergy. 2015;70(11):1393-1405.
11. Bilò MB, Ollert M, Blank S. The role of component-resolved diagnosis
in Hymenoptera venom allergy. Current Opinion in Allergy and
Clinical Immunology. 2019;19(6).
12. Luengo O, Cardona V. Component resolved diagnosis: when should it be
used? Clinical and Translational Allergy. 2014;4(1):28.
13. Stringari G, Tripodi S, Caffarelli C, et al. The effect of
component-resolved diagnosis on specific immunotherapy prescription in
children with hay fever. Journal of Allergy and Clinical
Immunology. 2014;134(1):75-81.e72.
14. Huang HJ, Resch-Marat Y, Rodriguez-Dominguez A, et al.
Underestimation of house dust mite-specific IgE with extract-based
ImmunoCAPs compared with molecular ImmunoCAPs. J Allergy Clin
Immunol. 2018;142(5):1656-1659 e1659.
15. Huang Y, Wang C, Lin X, et al. Association between
component-resolved diagnosis of house dust mite and efficacy of allergen
immunotherapy in allergic rhinitis patients. Clin Transl Allergy.2019;9:64.
16. Dang TD, Tang M, Choo S, et al. Increasing the accuracy of peanut
allergy diagnosis by using Ara h 2. J Allergy Clin Immunol.2012;129(4):1056-1063.
17. Lieberman JA, Glaumann S, Batelson S, Borres MP, Sampson HA, Nilsson
C. The utility of peanut components in the diagnosis of IgE-mediated
peanut allergy among distinct populations. J Allergy Clin Immunol
Pract. 2013;1(1):75-82.
18. Treudler R, Simon JC. Overview of component resolved diagnostics.Curr Allergy Asthma Rep. 2013;13(1):110-117.
19. Köhler J, Blank S, Müller S, et al. Component resolution reveals
additional major allergens in patients with honeybee venom allergy.Journal of Allergy and Clinical Immunology.2014;133(5):1383-1389.e1386.
20. Matthiesen F, Løwenstein H. Group V allergens in grass pollens. II.
Investigation of group V allergens in pollens from 10 grasses.Clinical & Experimental Allergy. 1991;21(3):309-320.
21. Ong EK, Knox RB, Singh MB. Mapping of the antigenic and allergenic
epitopes of Lol p VB using gene fragmentation. Molecular
Immunology. 1995;32(4):295-302.
22. Tamborini E, Faccini S, Lidholm J, et al. Biochemical and
Immunological Characterization of Recombinant Allergen Lol p 1.European Journal of Biochemistry. 1997;249(3):886-894.
23. Niederberger V, Laffer S, Froschl R, et al. IgE antibodies to
recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2)
account for a high percentage of grass pollen-specific IgE. J
Allergy Clin Immunol. 1998;101(2 Pt 1):258-264.
24. Hew M, Lee J, Varese N, et al. Epidemic thunderstorm asthma
susceptibility from sensitization to ryegrass (Lolium perenne) pollen
and major allergen Lol p 5. Allergy. 2020.
25. Knox RB. Grass pollen, thunderstorms and asthma. Clin Exp
Allergy. 1993;23(5):354-359.
26. O’Hehir RE, Varese NP, Deckert K, et al. Epidemic Thunderstorm
Asthma Protection with Five-Grass Pollen Tablet Sublingual
Immunotherapy: A Clinical Trial. Am J Respir Crit Care Med.2018;198(1):126-128.
27. Müller U, Schmid-Grendelmeier P, Hausmann O, Helbling A. IgE to
recombinant allergens Api m 1, Ves v 1, and Ves v 5 distinguish double
sensitization from crossreaction in venom allergy. Allergy.2012;67(8):1069-1073.
28. Müller UR, Johansen N, Petersen AB, Fromberg-Nielsen J, Haeberli G.
Hymenoptera venom allergy: analysis of double positivity to honey bee
and Vespula venom by estimation of IgE antibodies to species-specific
major allergens Api m1 and Ves v5. Allergy. 2009;64(4):543-548.
29. Jakob T, Müller U, Helbling A, Spillner E. Component resolved
diagnostics for hymenoptera venom allergy. Current opinion in
allergy and clinical immunology. 2017;17(5):363-372.
30. Whitrow MJ, Moore VM, Rumbold AR, Davies MJ. Effect of supplemental
folic acid in pregnancy on childhood asthma: a prospective birth cohort
study. American journal of epidemiology. 2009;170(12):1486-1493.
31. Heeringa JJ, McKenzie CI, Varese N, et al. Induction of IgG2 and
IgG4 B-cell memory following sublingual immunotherapy for ryegrass
pollen allergy. Allergy. 2020;75(5):1121-1132.
32. Chan SK, Pomes A, Hilger C, et al. Keeping Allergen Names Clear and
Defined. Front Immunol. 2019;10:2600.
33. Pomes A, Davies JM, Gadermaier G, et al. WHO/IUIS Allergen
Nomenclature: Providing a common language. Mol Immunol.2018;100:3-13.
34. Förster E, Dudlerb T, Gmachl M, Aberer W, Urbanek R, Suter M.
Natural and recombinant enzymatically active or inactive bee venom
phospholipase A2 has the same potency to release
histamine from basophils in patients with Hymenoptera allergy.Journal of Allergy and Clinical Immunology. 1995;95(6):1229-1235.
35. Grobe K, Pöppelmann M, Becker W-M, Petersen A. Properties of group I
allergens from grass pollen and their relation to cathepsin B, a member
of the C1 family of cysteine proteinases. European Journal of
Biochemistry. 2002;269(8):2083-2092.
36. Apostolou E, Deckert K, Puy R, et al. Anaphylaxis to Gelofusine
confirmed by in vitro basophil activation test: a case series.Anaesthesia. 2006;61(3):264-268.
37. Kalina T, Flores-Montero J, van der Velden VHJ, et al. EuroFlow
standardization of flow cytometer instrument settings and
immunophenotyping protocols. Leukemia. 2012;26(9):1986-2010.
38. Edwards ESJ, Bosco JJ, Aui PM, et al. Predominantly
Antibody-Deficient Patients With Non-infectious Complications Have
Reduced Naive B, Treg, Th17, and Tfh17 Cells. Front Immunol.2019;10:2593.
39. Altmann F. The Role of Protein Glycosylation in Allergy.International Archives of Allergy and Immunology.2007;142(2):99-115.
40. Halim A, Carlsson MC, Madsen CB, et al. Glycoproteomic analysis of
seven major allergenic proteins reveals novel post-translational
modifications. Mol Cell Proteomics. 2015;14(1):191-204.
41. Strasser R. Plant protein glycosylation. Glycobiology.2016;26(9):926-939.
42. Rendj D, Wilson IBH, Paschinger K. The Glycosylation Capacity of
Insect Cells. 2008.
43. Shi X, Jarvis DL. Protein N-glycosylation in the baculovirus-insect
cell system. Curr Drug Targets. 2007;8(10):1116-1125.
44. Blank S, Michel Y, Seismann H, et al. Evaluation of different
glycoforms of honeybee venom major allergen phospholipase A2 (Api m 1)
produced in insect cells. Protein Pept Lett. 2011;18(4):415-422.
45. Koren A, Lunder M, Molek P, et al. Fluorescent labeling of major
honeybee allergens Api m 1 and Api m 2 with quantum dots and the
development of a multiplex basophil activation test. Allergy.2020;75(7):1753-1756.
46. Chirumbolo S, Vella A, Ortolani R, et al. Differential response of
human basophil activation markers: a multi-parameter flow cytometry
approach. Clin Mol Allergy. 2008;6:12.
47. Prussin C, Metcalfe DD. 5. IgE, mast cells, basophils, and
eosinophils. J Allergy Clin Immunol. 2006;117(2 Suppl
Mini-Primer):S450-456.
48. Knol EF. Requirements for effective IgE cross-linking on mast cells
and basophils. Molecular Nutrition & Food Research.2006;50(7):620-624.
49. Mukai K, Chinthrajah RS, Nadeau KC, Tsai M, Gaudenzio N, Galli SJ. A
new fluorescent-avidin–based method for quantifying basophil activation
in whole blood. Journal of Allergy and Clinical Immunology.2017;140(4):1202-1206.e1203.
50. Sturm GJ, Kranzelbinder B, Sturm EM, Heinemann A, Groselj-Strele A,
Aberer W. The basophil activation test in the diagnosis of allergy:
technical issues and critical factors. Allergy.2009;64(9):1319-1326.
51. Wagner N, Rudert M. Sensitivity and specificity of standardised
allergen extracts in skin prick test for diagnoses of IgE-mediated
respiratory allergies. Clinical and Translational Allergy.2019;9(1):8.